CNBC
01 Oct 2025, 12:56 UTC · 50w ago
Verdict
Headline leans bearish. We score PFE +0.80 across five claims.
Score contradicts the headline.
Leans bearish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
5 claims · scored −1 bearish … +1 bullish
The Trump administration established a precedent where pharmaceutical companies can secure exemptions from industry-specific tariffs by agreeing to voluntary drug price lowers and increasing domestic investment.
More positive than 98% of claims this week
Pfizer secured a three-year tariff exemption in exchange for a $70 billion investment in U.S. manufacturing and research and a commitment to lower drug prices.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 91% of claims this week
The administration indicated that Eli Lilly is expected to be the next company to strike a similar pricing and investment deal.
More positive than 85% of claims this week
Gilead Sciences has significantly higher exposure to Medicaid (around 20% of domestic sales) compared to its peers.
More negative than 73% of claims this week
Pfizer agreed to sell existing drugs to Medicaid patients at 'most-favored-nation' pricing (the lowest price offered in other developed nations).
More negative than 66% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Reached a deal for tariff exemptions and saw a significant stock price increase.
More positive than 81% of ticker scores this week
Expected to strike a similar pricing deal and saw a stock price increase.
More positive than 76% of ticker scores this week
Stock price rose due to increased certainty regarding pharmaceutical tariffs.
More positive than 76% of ticker scores this week
Stock price rose as the Pfizer deal provided a roadmap to avoid punitive tariffs.
More positive than 70% of ticker scores this week
Stock price increased and analyst notes suggest low exposure to Medicaid pricing risks.
More positive than 70% of ticker scores this week
Stock price increased following the positive precedent set by the Pfizer agreement.
More positive than 66% of ticker scores this week
Listed as having made investments to build goodwill and benefit from a shift away from tariffs.
More positive than 66% of ticker scores this week
Listed as having made investments to build goodwill and benefit from a shift away from tariffs.
More positive than 66% of ticker scores this week
Listed as having made investments to build goodwill and benefit from a shift away from tariffs.
More positive than 60% of ticker scores this week
Identified as having low domestic revenue exposure to Medicaid pricing pressures.
More positive than 60% of ticker scores this week
Identified as having low domestic revenue exposure to Medicaid pricing pressures.
More negative than 73% of ticker scores this week
Highlighted as having significantly greater exposure to Medicaid pricing risks than its peers.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
9h ago
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market and negotiating pricing deals with the government.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
More positive than 35% of relationship scores this week
[mutual] Both are major pharmaceutical companies competing in the U.S. drug market.
+8.3%
Price agrees with the score
$27.59 vs $25.48 close before publication (Sep 30) · not market-adjusted
PFE chart →
